Clinical Trial

Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients

Recruiting
View on ClinicalTrials.gov →
Summary
Morbid obesity, is known to be associated with a high risk of VTE and, unfortunately, fixed doses of anticoagulant regimens may not provide optimal VTE prophylaxis in these patients especially after surgery.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-10-05; most recent amendment 2026-01-12.
Status change: Not Yet Recruiting → Recruiting 2023-01-08
Trial Details
NCT Number NCT05569681
Lead Sponsor Hawler Medical University
Conditions Morbid Obesity
Enrollment 2,400 participants
Start Date 2023-01-07
Primary Completion 2026-09-02 (estimated)
Study Completion 2026-10-02 (estimated)
Updated on ClinicalTrials.gov 2026-01-13